Pfizer and BioNTech Aim to Start Testing Coronavirus Vaccines in Humans by Late April Pfizer and BioNTech Aim to Start Testing Coronavirus Vaccines in Humans by Late April The two drugmakers also revealed financial details of their SARS-CoV-2 vaccine collaboration. Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced on Thursday that they intend to advance multiple SARS-CoV-2 vaccine candidates into human clinical testing, with the first clinical trials potentially beginning by late April. The two companies began their collaboration focused on developing a vaccine for the coronavirus that causes COVID-19 in March. Details of the collaboration Pfizer will pay $185 million upfront to BioNTech -- $72 million in cash and $113 million as an equity investment. BioNTech also could receive future milestone payments of up to $563 million. Pfizer is funding all vaccine development costs initially, but BioNTech will repay half of those costs to Pfizer from sales of COVID-19 vaccines developed through the collaboration, assuming the companies' efforts are successful. The two drugmakers plan to work together in evaluating COVID-19 vaccine candidates in the U.S. and Europe. If a vaccine wins the necessary regulatory approvals, they will co-market it worldwide, except in China, where BioNTech already has a collaboration agreement with Fosun Pharma. Read more They got to get this going before they are exposed for fraud https://www.fool.com/investing/2020/04/09/pfizer-and-biontech-aim-to-start-testing-coronavir.aspx?fbclid=IwAR1n_fJrGVp9gio99bZf5jNsK4747b0p-lYhJMVWnyNvkbyDdAkFaYSsnJs